Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study

BACKGROUND: Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in castration‐resistant prostate cancer (CRPC) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyväkkä, Anniina, Kääriäinen, Okko‐Sakari, Utriainen, Tapio, Löyttyniemi, Eliisa, Mattila, Kalle, Reinikainen, Petri, Sormunen, Jorma, Jääskeläinen, Minna, Auvinen, Päivi, Minn, Heikki, Sundvall, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972699/
https://www.ncbi.nlm.nih.gov/pubmed/36156455
http://dx.doi.org/10.1002/cam4.5262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972699/
https://www.ncbi.nlm.nih.gov/pubmed/36156455
http://dx.doi.org/10.1002/cam4.5262

Ejemplares similares